EnVVeno Medical Appoints Andrew Cormack as Chief Commercial Officer to Spearhead VenoValve® Commercialization

enVVeno Medical Corporation, a pioneer in treating venous disease, announced on April 9, 2024, the appointment of Andrew Cormack as Chief Commercial Officer. This move marks a significant step in enVVeno's transition from a clinical stage to a commercial enterprise, aiming to monetize the innovative VenoValve®.

Andrew Cormack, with a rich background in both startup and leading medical device companies such as WallabyPhenox, Medtronic, and Covidien, brings to enVVeno an extensive experience in product launches. Cormack's expertise is expected to be pivotal in the commercialization strategy of the VenoValve®, a product he highly regards for its potential in addressing the unmet needs of millions suffering from Chronic Venous Insufficiency (CVI).

enVVeno is currently advancing the VenoValve®, a groundbreaking surgical venous valve replacement for patients with severe CVI due to valvular incompetence in the deep venous system. The condition, mainly caused by deep vein thromboses, leads to symptoms such as swelling, pain, edema, and in severe cases, venous ulcers. enVVeno estimates approximately 2.5 million potential U.S. candidates annually for the VenoValve®.

The company has revealed promising six-month efficacy data from the SAVVE U.S. pivotal study, showing significant clinical improvement in 97% of participants. With the study fully enrolled in September 2023, enVVeno plans to file a PMA application for FDA approval of the VenoValve® in Q4 of 2024, following the FDA's request for a minimum of one-year data on all study participants.